Association between phosphorylated AMP-activated protein kinase and acetyl-CoA carboxylase expression and outcome in patients with squamous cell carcinoma of the head and neck

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Su, Ying Wen ^a   Lin, Yun Ho ^b   Pai, Man Hui ^c   Lo, An Chi ^a   Lee, Yu Chieh ^c   Fang, I Chih ^a   Lin, Johnson ^a   Hsieh, Ruey Kuen ^a   Chang, Yi Fang ^a   Chen, Chi Long ^d  

^a MACKAY MEMORIAL HOSPITAL   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; ADENYLATE KINASE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOPROTEIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROTEIN EXPRESSION; SCORING SYSTEM; TISSUE MICROARRAY; UPREGULATION; VERY ELDERLY; ADJUVANT THERAPY; CARCINOMA, SQUAMOUS CELL; ENZYMOLOGY; HEAD AND NECK NEOPLASMS; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PHOSPHORYLATION; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN PROCESSING; SECONDARY; TREATMENT OUTCOME;

ACETYL-COA CARBOXYLASE; ADENYLATE KINASE; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; PHOSPHOPROTEINS; PHOSPHORYLATION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTEIN PROCESSING, POST-TRANSLATIONAL; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84899747305     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0096183     Document Type: Article

References (36)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917.
2. Mehanna H, Paleri V, West CM, Nutting C (2010) Head and neck cancer- Part 1: Epidemiology, presentation, and prevention. BMJ 341: c4684.
3. Dietrich T, Reichart PA, Scheifele C (2004) Clinical risk factors of oral leukoplakia in a representative sample of the US population. Oral Oncol 40: 158-163. (Pubitemid 38030359)
4. Dikshit RP, Ramadas K, Hashibe M, Thomas G, Somanathan T, et al. (2006) Association between diabetes mellitus and pre-malignant oral diseases: a cross sectional study in Kerala, India. Int J Cancer 118: 453-457. (Pubitemid 41779086)
5. Albrecht M, Banoczy J, Dinya E, Tamas G Jr (1992) Occurrence of oral leukoplakia and lichen planus in diabetes mellitus. J Oral Pathol Med 21: 364-366.
6. Stott-Miller M, Chen C, Chuang SC, Lee YC, Boccia S, et al. (2012) History of diabetes and risk of head and neck cancer: a pooled analysis from the international head and neck cancer epidemiology consortium. Cancer Epidemiol Biomarkers Prev 21: 294-304.
7. Hardie DG, Carling D (1997) The AMP-activated protein kinase-fuel gauge of the mammalian cell? Eur J Biochem 246: 259-273. (Pubitemid 27232500)
8. Ruderman N, Prentki M (2004) AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome. Nat Rev Drug Discov 3: 340-351. (Pubitemid 38499761)
9. Luo Z, Saha AK, Xiang X, Ruderman NB (2005) AMPK, the metabolic syndrome and cancer. Trends Pharmacol Sci 26: 69-76. (Pubitemid 40170168)
10. Jin Q, Feng L, Behrens C, Bekele BN, Wistuba II, et al. (2007) Implication of AMP-activated protein kinase and Akt-regulated survivin in lung cancer chemopreventive activities of deguelin. Cancer Res 67: 11630-11639.
11. Swinnen JV, Beckers A, Brusselmans K, Organe S, Segers J, et al. (2005) Mimicry of a cellular low energy status blocks tumor cell anabolism and suppresses the malignant phenotype. Cancer Res 65: 2441-2448. (Pubitemid 40490156)
12. Rattan R, Giri S, Hartmann LC, Shridhar V (2011) Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner. J Cell Mol Med 15: 166-178.
13. Vitale-Cross L, Molinolo AA, Martin D, Younis RH, Maruyama T, et al. (2012) Metformin prevents the development of oral squamous cell carcinomas from carcinogen-induced premalignant lesions. Cancer Prev Res 5: 562-573.
14. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, et al. (2010) American Joint Committee on Cancer Staging Manual. New York, Springer.
15. William WN, Kim JS, Liu DD, Solis L, Behrens C, et al. (2012) The impact of phosphorylated AMP-activated protein kinase expression on lung cancer survival. Ann Oncol 23: 78-85.
16. Hadad SM, Baker L, Quinlan PR, Robertson KE, Bray SE, et al. (2009) Histologic evaluation of AMPK signalling in primary breast cancer. BMC Cancer 9: 307.
17. Park HU, Suy S, Danner M, Dailey V, Zhang Y, et al. (2009) AMP-activated protein kinase promotes human prostate cancer cell growth and survival. Mol Cancer Ther 8: 733-741.
18. Lee CC, Ho HC, Hsiao SH, Huang TT, Lin HY, et al. (2012) Infectious complications in head and neck cancer patients treated with cetuximab: propensity score and instrumental variable analysis. PLoS One 7: e50163.
19. Sanli T, Rashid A, Liu C, Harding S, Bristow RG, et al. (2010) Ionizing radiation activates AMP-activated kinase (AMPK): a target for radiosensitization of human cancer cells. Int J Radiat Oncol Biol Phys 78: 221-229.
20. Temam S, Kawaguchi H, El-Naggar AK, Jelinek J, Tang H, et al. (2007) Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol 25: 2164-2170. (Pubitemid 46954638)
21. Ronnebaum SM, Joseph JW, Ilkayeva O, Burgess SC, Lu D, et al. (2008) Chronic suppression of acetyl-CoA carboxylase 1 in beta-cells impairs insulin secretion via inhibition of glucose rather than lipid metabolism. J Biol Chem 283: 14248-14256.
22. Zu X, Zhong J, Luo D, Tan J, Zhang Q, et al. (2013) Chemical genetics of acetyl-CoA carboxylases. Molecules 18: 1704-1719.
23. Abu-Elheiga L, Matzuk MM, Kordari P, Oh W, Shaikenov T, et al. (2005) Mutant mice lacking acetyl-CoA carboxylase 1 are embryonically lethal. Proc Natl Acad Sci 102: 12011-12016. (Pubitemid 41291120)
24. Park SH, Gammon SR, Knippers JD, Paulsen SR, Rubink DS, et al. (2002) Phosphorylation-activity relationships of AMPK and acetyl-CoA carboxylase in muscle. J Appl Physiol 92: 2475-2482. (Pubitemid 34666373)
25. Magnard C, Bachelier R, Vincent A, Jaquinod M, Kieffer S, et al. (2002) BRCA1 interacts with acetyl-CoA carboxylase through its tandem of BRCT domains. Oncogene 21: 6729-6739. (Pubitemid 35221915)
26. Shen Y, Tong L (2008) Structural evidence for direct interactions between the BRCT domains of human BRCA1 and a phospho-peptide from human ACC1. Biochemistry 47: 5767-5773. (Pubitemid 351747055)
27. Moreau K, Dizin E, Ray H, Luquain C, Lefai E, et al. (2006) BRCA1 affects lipid synthesis through its interaction with acetyl-CoA carboxylase. J Biol Chem 281: 3172-3181. (Pubitemid 43845927)
28. Bandyopadhyay S, Zhan R, Wang Y, Pai SK, Hirota S, et al. (2006) Mechanism of apoptosis induced by the inhibition of fatty acid synthase in breast cancer cells. Cancer Res 66: 5934-5940. (Pubitemid 43927149)
29. Chajes V, Cambot M, Moreau K, Lenoir GM, Joulin V (2006) Acetyl-CoA carboxylase alpha is essential to breast cancer cell survival. Cancer Res 66: 5287-5294. (Pubitemid 43844953)
30. Brusselmans K, De Schrijver E, Verhoeven G, Swinnen JV (2005) RNA interference-mediated silencing of the acetyl-CoA-carboxylase-alpha gene induces growth inhibition and apoptosis of prostate cancer cells. Cancer Res 65: 6719-6725. (Pubitemid 41060709)
31. Swinnen JV, Brusselmans K, Verhoeven G (2006) Increased lipogenesis in cancer cells: new players, novel targets. Curr Opin Clin Nutr Metab Care 9: 358-365. (Pubitemid 44101970)
32. Kim KH (1997) Regulation of mammalian acetyl-coenzyme A carboxylase. Annu Rev Nutr 17: 77-99.
33. Frederick MJ, VanMeter AJ, Gadhikar MA, Henderson YC, Yao H, et al. (2011) Phosphoproteomic analysis of signaling pathways in head and neck squamous cell carcinoma patient samples. Am J Pathol 178: 548-571.
34. Chu PY, Hsu NC, Lin SH, Hou MF, Yeh KT (2012) High nuclear protein kinase CbII expression is a marker of disease recurrence in oral squamous cell carcinoma. Anticancer Res 32: 3987-3991.
35. Gapany M, Faust RA, Tawfic S, Davis A, Adams GL, et al. (1995) Association of elevated protein kinase CK2 activity with aggressive behavior of squamous cell carcinoma of the head and neck. Mol Med 1: 659-666.
36. Mehra R, Cohen RB, Burtness BA (2008) The role of cetuximab for the treatment of squamous cell carcinoma of the head and neck. Clin Adv Hematol Oncol 6: 742-750.